Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria.

NCT ID: NCT02089841

Last Updated: 2014-03-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 140 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-05-31
• Study Completion Date: 2013-08-31

Brief Summary

Artemether-lumefantrine has been used in Tanzania as first-line treatment for uncomplicated malaria since 2007. Nonetheless, a report of increased proportion of patients with parasitaemia on day 1 following treatment with artemisinin based combination therapies has emerged from Kenya. Similarly, resistance against artemisinins has been confirmed in South-East Asia and it can spread to Africa. Therefore, the purpose of this study was to assess the efficacy of Artemether-lumefantrine for the treatment of uncomplicated malaria among children after five years of wide scale use of the drug in Tanzania.

Detailed Description

Artemisinin based combination therapies (ACTs) are currently recommended by the World Health Organization (WHO) as first-line treatment for uncomplicated malaria in all malaria endemic countries including Tanzania, that adopted the policy in 2007. ACTs have proven to be highly efficacious in different parts of the world with different malaria endemicity. Artemisinins clear asexual parasites rapidly and they are also potent against P. falciparum gametocytes, hence reducing disease transmission and spread of drug resistance. Nonetheless, a report in Kenya shows an increase in proportion of patients with parasitaemia on day 1. Most recently, resistance against artemisinins has been confirmed in four countries of South-East Asia, and it may spread to Africa.

In order to safeguard ACTs life span, WHO recommends all suspected malaria cases to be confirmed with parasitological diagnosis, followed by prompt treatment with effective antimalarials. It also emphasizes on the need to conduct efficacy studies for the first and second line antimalarial treatments after every two years so as to be able to detect resistance early on its course. Therefore, based on this notion, this study aimed to assess the therapeutic efficacy of Artemether/Lumefantrine among children with uncomplicated falciparum malaria in Bagamoyo district, five years after its wide scale use in Tanzania.

Conditions

Plasmodium Falciparum Malaria

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Artemether/lumefantrine

In this single-arm study, patients will be treated with Artemether/lumefantrine, and the first, third and fifth doses of the drug will be given under the direct observation of the health workers. The patients will be followed-up for 42 days, on day 1, 2, 3, 7, 14, 21, 28 and 42 to assess the efficacy of the drug.

Group Type: EXPERIMENTAL

Artemether-lumefantrine

Intervention Type: DRUG

Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.

Interventions

Artemether-lumefantrine

Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.

Intervention Type: DRUG

Other Intervention Names

Coartem

Eligibility Criteria

Inclusion Criteria

• Mono-infection with P. falciparum
• Parasitaemia level of 2000 - 200,000/μL
• Absence of danger signs or signs of severe malaria
• Axillary temperature ≥ 37.5°C or history of fever 24 hours prior to coming to the facility
• Absence of other concomitant infections like pneumonia which can cause fever
• No use of antimalarial drug two weeks prior to the study
• Consent to comply to the protocol.

Exclusion Criteria

• Presence of general danger signs or signs of severe falciparum malaria
• Severe malnutrition
• Febrile condition due to diseases other than malaria, such as measles, acute lower respiratory infection or other known chronic diseases
• Regular medication which might interfere with antimalarial pharmacokinetics
• History of hypersensitivity reactions or contraindications to any medicine being used in the trial.

• Minimum Eligible Age: 6 Months
• Maximum Eligible Age: 120 Months
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Karolinska Institutet

OTHER

Sponsor Role: collaborator

Richard Mwaiswelo

OTHER

Sponsor Role: lead

Responsible Party

Richard Mwaiswelo

Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Andreas Martensson, PhD

Role: STUDY_DIRECTOR

Karolinska Institutet

Locations

Muhimbili University of Health and Allied Sciences

Dar es Salaam, , Tanzania

Countries

Tanzania

Other Identifiers

3.0.2011

Identifier Type: -

Identifier Source: org_study_id